Salma Jabbour, MD, on the Design of the Ongoing KEYNOTE-799 Study
The KEYNOTE-799 study is evaluating pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
In an interview with CancerNetwork®, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, explained the design of the ongoing KEYNOTE-799 study (NCT03631784) which is evaluating pembrolizumab (Keytruda) plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.
Transcription:
KEYNOTE-799 is a phase 2, open-label, non-randomized study which evaluated pembrolizumab with concurrent chemoradiation therapy for stage III unresectable non–small cell lung cancer.
In cohort A, patients received carboplatin, paclitaxel, and pembrolizumab for 1 cycle; followed by concurrent chemoradiation therapy with the same agents of carboplatin, paclitaxel, and pembrolizumab; followed by consolidative pembrolizumab for cycles 4 to 17. And that cohort A consisted [of] patients with both squamous and nonsquamous histology.
Cohort B consisted of patients with only nonsquamous histology and patients received cisplatin, pemetrexed, and pembrolizumab for 1 cycle; followed by concurrent cisplatin, pemetrexed, and pembrolizumab with 60 Gy of radiation therapy daily; followed by consolidative pembrolizumab.
The primary end points of this study were objective response rate [by] blinded independent central review using RECIST 1.1 as well as the rates of grade 3 or higher pneumonitis.
